

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01K 61/00, 67/00, C12N 15/12, 15/18, 15/85, 15/87, 15/90		A1	(11) International Publication Number: WO 95/20872 (43) International Publication Date: 10 August 1995 (10.08.95)
(21) International Application Number: PCT/US95/01477 (22) International Filing Date: 2 February 1995 (02.02.95) (30) Priority Data: 08/191,494 4 February 1994 (04.02.94) US 08/192,272 4 February 1994 (04.02.94) US 08/286,872 5 August 1994 (05.08.94) US (60) Parent Applications or Grants (63) Related by Continuation US 08/191,494 (CIP) Filed on 4 February 1994 (04.02.94) US 08/192,272 (CIP) Filed on 4 February 1994 (04.02.94) US 08/286,872 (CIP) Filed on 5 August 1994 (05.08.94) (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Stanford, CA 94305 (US). (71) Applicant (for US only): MADSEN, Annamae, L. (legal representative of the deceased inventor) [US/US]; 811 Caroline, Port Angeles, WA 98362 (US).		(72) Inventor: HEREFORD, Lynna, Madsen (deceased). (72) Inventors; and (75) Inventors/Applicants (for US only): POWERS, Dennis, Alpha [US/US]; Hopkins Marine Station, Stanford University, Oceanview Boulevard, Pacific Grove, CA 93950 (US). GOMEZ-CHIARRI, Marta [ES/US]; 706 Crocker Avenue, Pacific Grove, CA 93950 (US). (74) Agent: FABIAN, Gary, R.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>	
(54) Title: GENETIC ENGINEERING OF MOLLUSKS			
(57) Abstract <p>The present invention describes vectors and methods useful for the production of transgenic mollusks, in particular, transgenic abalone. The invention further describes transgenic mollusks having enhanced growth properties. In addition, the isolation and characterization of an abalone actin gene promoter region is disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

GENETIC ENGINEERING OF MOLLUSKS

FIELD OF THE INVENTION

5 The present invention relates to transgenic mollusks, in particular shellfish, and further to methods of genetic engineering of mollusks, including abalone. Further, the invention relates to the isolation and characterization of abalone actin gene
10 sequences, and uses thereof.

REFERENCES

- Agellon, L.B., et al., *Can. J. Fish. Aquat. Sci.* 45:146-151 (1988).
- 15 Ausubel, F. M., et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., Media PA.
- Bellen, H.J., et al., *Genes Dev.* 3:1288-1300 (1989).
- Chong, S.S.C., and Vielkind, J.R., *Theor. Appl.*
20 *Genet.* 78:369-380 (1989).
- Crea, R., U. S. Patent No. 4,888,286, issued December 19, 1989.
- Davies, J.A., et al., *J. Mol. Biol.* 189(1):13-24 (1986).
- 25 de Wet, J.R., et al., *Mol. Cell. Biol.* 7:725-737 (1987).
- Du, S.J., et al., *Bio/Technology* 10:176-181 (1992).
- Eaton, M. A. W., et al., U. S. Patent No.
30 4,719,180, issued Jan. 12, 1988.
- Ebert, E.E., "Abalone Aquaculture: A North America Regional Review" in Abalone of the World: Biology, Fisheries and Culture (Shepherd, S.A., et al., eds.) Blackwell Scientific Publications Ltd., Oxford,
35 England, pp. 570-180 (1992).
- Frohman, M.A., et al., *Proc. Natl. Acad. Sci. USA* 85:8998-9002 (1988).
- Frohman, M.A., in PCR Protocol: A Guide to Methods and Applications, p.28, Academic Press (1990).

- Fryberg, E.A., et al., *Cell* **33**:115-123 (1983).
- Gibbs, P.D.L., et al., *2nd Int. Marine Biotech. Conf. (IMBC)* Baltimore, MD, Abstracts, p. 79 (1991).
- Gonzalez-Villansenor, L.I., et al., *Gene* **65**, pp. 239-246.
- Gorman, C.M., et al., *Mol. Cell. Biol.*, **2**:1044 (1982).
- Gutzman del Proo, A., "A Review of Abalone and its Fishery in Mexico" in Abalone of the World: Biology, Fisheries and Culture (Shepherd, S.A., et al., eds.) Blackwell Scientific Publications Ltd., Oxford, England, pp. 438-447 (1992).
- Guyomard, R.D., et al., *Biochimie* **71**:85-863 (1989).
- Hackett, P.B., "The Molecular Biology of Transgenic Fish" in Molecular Biology of Fishers, Vol. 2 (Hochachka, P., and Mommsen, T., eds.) in press (1993).
- Hahn, K.O., in Handbook of Culture of Abalone and Other Marine Gastropods (Hahn, ed.) CRC Press, Inc., Boca Raton, FL, pp. 71-98 (1989).
- Hammer, R.E., et al., *Nature* **315**:680-683 (1985).
- Harvey, D., *USDA Aqua-5* pp. 19 (1990).
- Henikoff, S., *Methods Enzymol.* **155**:156-165 (1987).
- Hitzeman, R.A., et al., US Patent No. 4,775,622, issued Oct. 4, 1988.
- Hoheisel, J., and Pohl, F.M., *Nucl. Acids Res.* **14**:3605 (1986).
- Irvine, et al., *Development* **111**:407-424 (1991).
- Joosse, J., and Garaerts, W.P.M., "Endocrinology" in The Mollusca, Vol. 4, Physiology, Part I (Saleuddin, A.S.M., and Wilber, K.M., eds.) Academic Press, London, England, pp. 317-406 (1983).
- Kawasaki, E.S., et al., in PCR Technology: Principles and Applications of DNA Amplification (H.A. Erlich, ed.) Stockton Press (1989).
- Koelle, M., et al., *Cell* **67**:59-77 (1991).

Koelle, Michael, "Molecular Analysis of the *Drosophila Melanogaster* Ecdysone Receptor Complex," Ph.D. thesis, Stanford University 1992.

5 Liu, Z.B., et al., *Mol. Cell. Biol.* 10:3432-3440 (1990a).

Liu, Z.B., et al., *Bio/Technology* 8:1268-1272 (1990b).

Liu, Z.B., et al., *DNA Sequence* 1:125-136 (1990c).

10 Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1982).

Moav, B., et al., in "Expression of Heterologous Genes in Transgenic Fish" in Transgenic Fish (Hew, C.L., ed.) World Scientific Publishing Co., Singapore, pp. 120-141 (1992a).

15 Moav, B., et al., *Mol. Mar. Bio. Biotech.* 1:338-345 (1992b).

Moriyama, S.S., et al., *Xth Internal Symp. on Comp. Endocrin. Abstracts*, Malaga, Spain, pp. 243 (1989).

20 Moriyama, Ph.D. Thesis, University of Kitsato (in Japanese) 1992.

Morse, E.D., *Biennial Rpt., U. of California Sea Grant Program*, pp. 83-87 (1981).

Morse, E.D., *Aquaculture* 39:263-282 (1984).

25 Mullis, K.B., U.S. Patent No. 4,683,202, issued 28 July 1987.

Mullis, K.B., et al., U.S. Patent No. 4,683,195, issued 28 July 1987.

30 Oeda, K., et al., U.S. Patent No. 4,766,068, issued Aug. 23, 1988.

Paynter, K.T., and Chen, T.T., *Biol. Bull.* 181:459-462 (1991).

35 Prince, J.D., and Shepherd, "Australian Abalone Fisheries and Their Management" in Abalone of the World: Biology, Fisheries and Culture (Shepherd, S.A., et al., eds.) Blackwell Scientific Publications Ltd., Oxford, England, pp. 407-426 (1992).

Rio, R.C., et al., *Mol. Cell. Biol.* 5(8):1833 (1985).

Rokkones, E.P., et al., *J. Comp. Physiol. B.* 158:751-758 (1989).

5 Rutter, W.J., et al., U.S. Patent No. 4,769,238, issued Sept. 6, 1988.

Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, NY (1989).

10 Sara, V.R., and Hall, K., *Physiological Rev.* 70:591-614 (1990).

Schweinfest, C.W., et al., *Gene* 71(1):207 (1988).

Sekine, S., et al., *Proc. Natl. Acad. Sci. USA* 82:4306-4310 (1985).

15 Stuart, G.W., et al., *Development* 103:403-412 (1988).

Tarr, R.J.K., "The Abalone Fishery of Mexico" in Abalone of the World; Biology, Fisheries and Culture (Shepherd, S.A., et al., eds.) Blackwell Scientific Publications Ltd., Oxford, England, pp. 438-447 (1992).

20 Tegner, M.J., et al., "The California Red Abalone Fishery: A Case Study in Complexity" in Abalone of the World; Biology, Fisheries and Culture (Shepherd, S.A., et al., eds.) Blackwell Scientific Publications Ltd., Oxford, England, pp. 370-383 (1992).

Vanderkerckhove, J., and Weber, K., *Proc. Natl. Acad. Sci. USA* 75:1106-1110 (1978a).

Vanderkerckhove, J., and Weber, K., *Eur. J. Biochem.* 90:451-462 (1978b).

30 Yoshio, T., et al., U. S. Patent No. 4,849,350, issued July 18, 1989.

Zhang, P., et al., *Mol. Rep. Dev.* 25:3-13 (1990).

Zhu, Z., et al., *Kexue Tongbau* 31:998-405 (1986).

35 BACKGROUND OF THE INVENTION

The U.S. market for seafood is large and growing with per capita seafood consumption rising 23% in the

last decade. During this period, the consumer price index for seafood jumped 244%, while red meat prices rose only half that amount. Despite efforts to manage wild finfish and shellfish populations at a sustained yield level, the U.S. consumers increasingly greater amounts than it produces from its fishers, thus depleting the resource. Ocean harvests worldwide are expected to meet only 90 million metric tons of the projected demand of 114 million metric tons in the year 2000 (Harvey, 1990).

This global picture is mirrored in the California abalone industry. From 1931 until 1968, commercial abalone landings averaged around 900 metric tons a year. Since 1968, landings have decreased to approximately 15% of these levels. This decline has been attributed to a number of factors, the most important of which is probably fishing pressure brought about by demand from the Far East (Tegner, 1989).

Despite intensive efforts by the California Department of Fish and Game to restore the fishery, current landings remain at their 1968 levels. The decline in the California abalone fishery is paralleled by similar declines in Mexico (Gutzman del Proo, 1992), South Africa (Tarr, 1992), and Australia (Prince and Shepherd, 1992).

As the supply of abalone diminishes, their per limit value continues to increase. Between 1973 and 1988, the price paid to divers has increased 800%, over twice the rate of inflation (Tegner, et al., 1992). This increased demand has led to the development of techniques for commercial cultivation. These efforts have been concentrated mainly in Japan and California, although California is unique in the development of seawater systems for intensive cultivation on land (Ebert, 1992).

SUMMARY OF THE INVENTION

In one aspect the present invention includes a transgenic mollusk containing a DNA sequence heterologous to the mollusk. The heterologous DNA sequence may be integrated or extrachromosomal. In one embodiment the DNA sequence is flanked by regulatory sequences, which are effective to allow expression of the DNA sequence in the mollusk (e.g., expression of an RNA or protein). These regulatory sequences can be derived from a mollusk, such as abalone, or from other sources, including *Drosophila melanogaster* genes. Embodiments of the invention include use of actin gene regulatory sequences from either *Drosophila melanogaster* or abalone. A preferred embodiment utilizes the actin gene promoter described herein.

In one embodiment of the invention, the regulatory sequences are derived from the *Drosophila melanogaster* ACT-5 promoter and the heterologous DNA sequence encodes coho salmon growth hormone. When this construct is used to generate transgenic abalone, growth of the abalone is enhanced.

Heterologous DNA sequences useful in the practice of the present invention include DNA sequences that encode products that promote growth enhancement (e.g., a growth hormone or insulin-like growth factor). Further included are other DNA sequences encoding products affecting the taste or texture of mollusk tissue.

The present invention also includes expression vectors useful for making transgenic mollusks by the method of the present invention. Expression vectors typically include (i) a first DNA sequence flanked by regulatory elements effective to allow expression of the sequence in a mollusk, wherein the regulatory elements are derived from a mollusk gene, and (ii) second DNA sequences allowing the propagation of the vector in a secondary host. Exemplary second sequences

include DNA sequences having an origin of replication and a selectable marker, which are both functional in the secondary host. Secondary hosts include bacteria, yeast and insect cells. The expression vectors can
5 carry the regulatory elements and DNA coding sequences discussed above.

In another embodiment, the present invention includes an expression vector containing an abalone actin gene promoter region adjacent a cloning site
10 useful to facilitate the insertion of any coding sequence of interest.

The present invention also includes a method for transfecting a mollusk. In the method, a vector is provided which contains DNA sequences of interest. The
15 vector is introduced into a selected mollusk, for example, by electroporation. Transfected mollusks, that is, mollusks now bearing the DNA of interest, are identified based on the presence of the DNA sequence, for example, by hybridization analysis or by
20 manifestation of a characteristic associated with the DNA sequence (e.g., presence of a reporter gene).

The DNA sequence can encode a gene that promotes growth enhancement, such as, a growth factor or an insulin-like growth factor.

25 The introduced DNA may be integrated or extra-chromosomal. In one embodiment, introduction of the DNA is accomplished by electroporating the vector into a fertilized mollusk egg, for example, a fertilized abalone egg. Typically, the DNA sequence is flanked by
30 regulatory sequences which are effective to allow expression of the DNA sequence in the transgenic mollusk.

Another embodiment of the present invention includes a method for the recombinant expression of a
35 protein in a mollusk. The method includes using a transgenic mollusk carrying a heterologous DNA sequence

encoding a protein grown under conditions permissive for the expression the protein.

The invention further includes a method for enhancing the growth of a mollusk, where a transgenic mollusk is generated that carries a heterologous DNA sequence encoding a gene that promotes growth enhancement (e.g., a growth hormone or insulin-like growth factor). The transgenic mollusk is then cultured under conditions permissive for the growth enhancing protein.

The present invention also includes a duplex DNA fragment containing a DNA sequence encoding a polypeptide, and adjacent the DNA sequence, a promoter effective to promote transcription of the polypeptide, where the promoter is an abalone actin gene promoter and the DNA sequence is not the abalone actin gene. In this embodiment, the polypeptide coding sequences are heterologous to the promoter sequences. In one embodiment, the DNA sequence is a gene that promotes growth enhancement, such as, a growth hormone (e.g., coho salmon growth hormone) or insulin-like growth factor.

Such duplex DNA fragments are useful, for example, as expression cassettes for insertion into any vector of interest.

In another aspect, the invention includes a method for the production of a polyploid mollusk, for example, abalone. In the method, a fertilized abalone egg is treated with cytochalasin B to induce polyploidy. The treated egg is then cultured under conditions to allow development of the egg into a polyploid organism. In one embodiment, the treatment with cytochalasin B results in a greater than 70% inhibition of polar body formation. Such polyploid organisms are useful for their enhanced growth properties.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying drawings.

5

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 demonstrates uptake and retention of plasmid DNA into electroporated abalone eggs.

10 Figure 2 shows retention of electroporated DNA in three-month-old juvenile abalone.

Figure 3A shows a partial restriction map of potential junction fragments. Figure 3B shows DNA hybridization data for transgenic abalone.

15 Figure 4 represents expression of β -galactosidase in electroporated larvae.

Figure 5A shows a schematic of an actin gene and an internal 400 bp region. Figure 5B shows PCR amplification of actin-specific sequences.

20 Figure 6 shows a comparison of weight of abalone transformed with pLH3 with non-transgenic controls.

Figure 7 presents a schematic map of vector pMK26 containing the *Drosophila melanogaster* ACT 5C promoter.

25 Figures 8A and 8B schematically represents the steps involved in the isolation of the abalone actin promoter.

Figure 9 presents the sequence (SEQ ID NO:5) of the abalone actin promoter and adjacent regions.

Figure 10 presents a schematic of the structure of the abalone actin promoter.

30 Figure 11 presents a schematic map of vector pLUC containing the luciferase reporter gene.

Figure 12 presents a schematic map of vector pCMVtkLUC, a control plasmid containing the luciferase reporter gene.

35

DETAILED DESCRIPTION OF THE INVENTION

I. DEFINITIONS

Homologous DNA refers to DNA not introduced into a host organism by recombinant means.

Heterologous DNA refers to DNA which has been transfected into a host organism. Typically, heterologous DNA refers to DNA that is not originally derived from the transfected or transformed cells' genomic DNA (e.g., CAT and β -galactosidase gene sequences). However, any DNA introduced into an organism by recombinant means is referred to as heterologous DNA (e.g., introduction into an abalone of an expression vector carrying abalone growth hormone gene).

Extra-chromosomal DNA refers to plasmid DNA introduced into a host cell, where the plasmid DNA has not integrated into the genomic DNA of the host cell.

The term "mollusk" herein refers to members of the phylum Mollusca, including, the classes Bivalvia (e.g., oysters), Gastropoda (e.g., abalone), and Cephalopoda (e.g., squid).

II. DEVELOPMENT OF VECTORS USEFUL FOR THE GENERATION OF TRANSGENIC SHELLFISH

A. INTRODUCTION OF EXOGENOUS DNA

The development of an effective method for production of transgenic mollusks need to take into account certain peculiarities of the organisms. An exemplary mollusk, for the purposes of the present invention, is abalone.

Abalone belong to a loose group of marine invertebrates known as "broadcast spawners." In such organisms, fertilization is external and is preceded by the release of large numbers of sperm and eggs from gravid adults. A large adult female (7 inches) will produce on the order of 10 million eggs and, under hatchery conditions, fertilization rates greater than 95% are achieved.

Development proceeds rapidly and synchronously: Meiosis I (appearance of the first polar body) is

complete by 20 minutes; Meiosis II (appearance of the second polar body) is complete by 30 minutes, and the first cleavage is complete by 2 hours. By 24 hours, gastrulation is completed and a velum, a simple locomotory system for swimming, has developed.

At this point, the egg hatches, releasing a veliger larva. During the next 24 hours, the primary differentiation of virtually all adult tissue occurs, resulting in what is termed a trochophore larva. Trochophore development continues for five to seven days, at which time settlement occurs.

Settlement involves attachment of the animal to a solid substrate, after which it loses its swimming apparatus, develops an adult shell, and begins grazing. For reasons which are not well understood, settlement results in large mortalities -- under hatchery conditions, only two to five percent of competent veliger larvae successfully settle. While this is not a major hindrance to hatcheries, due to the high fecundity of the organism, it does impose problems for development of an efficient transgenic technology.

To improve the chances for integration of exogenous DNA into the germ-line, the DNA is introduced prior to the first mitotic cleavage. Introducing DNA by electroporation allows treatment of a large number of eggs within relatively short time frame of the first mitotic cleavage (approximately two hours). Although introduction of DNA by electroporation is a preferred embodiment of the invention, alternative approaches to introducing exogenous DNA may be used as well, such as microinjection.

A further consideration when dealing with the transfection of abalone is its position in the animal kingdom and the influence of this position upon the choice of suitable promoters for use in expression vectors. "Classic" vertebrate expression vectors usually employ promoters which are expressed at high

levels in a number of tissues. Most popular among these are the promoters derived from the long terminal repeats (LTRs) of the retroviruses cytomegalovirus (CMV) and Rous sarcoma virus (RSV).

5 However, because of the evolutionary distances separating vertebrates and mollusks, vertebrate promoters are not likely to effect expression in molluscan tissue. Experiments performed in support of the present invention have utilized *D. melanogaster*
10 promoters (e.g., ACT5-C; Koelle, 1993), an organism more closely related to mollusks than vertebrates. Other *D. melanogaster* promoters/expression vectors may also be useful in the practice of the present invention (e.g., Rio, et al., 1985; Davies, et al., 1986;
15 Schweinfest, et al., 1988).

Exemplary plasmid pMK18 is described in Example 1. Plasmid pMK18 contains the ACT5-C promoter, a β -actin promoter. This promoter was chosen because the gene is expressed throughout development, as well as in most
20 adult tissues (Fryberg, et al., 1983). The plasmid contains an "expression cassette" consisting of the *E. coli* β -galactosidase gene and the 5' untranslated region of the *ubx* gene.

Experiments performed in support of the present
25 invention utilized plasmid pMK18 for transfection of fertilized abalone eggs by electroporation. Initial optimization of electroporation conditions was accomplished using dot blot hybridization to detect introduction of exogenous DNA into the fertilized eggs
30 (Example 2). DNA was extracted from single eggs or larvae, which was then fixed to nitrocellulose and hybridized with the appropriate radiolabeled plasmid DNA.

Dot blots were performed at two time points: (i)
35 at the two-to-four cell stage -- to monitor DNA uptake, and (ii) immediately after hatching -- to monitor DNA retention. A typical dot blot after optimization of

electroporation conditions is shown in Figure 1 (Example 3). In the figure it can be seen that DNA is taken up and retained in approximately 80-100% of all electroporated eggs.

5 To test for expression of the exogenous DNA in the transgenic abalone, pools of fifty larvae were collected at various times during the period of larval development and assayed for β -galactosidase activity (Example 4). The results of these assays are shown in
10 Figure 4. The data demonstrate that β -galactosidase is expressed when pMK18 (β -actin promoter) is employed.

Activity is observed in trochophore larvae (day one), and this activity reaches a maximum in veliger larvae (day two). The decline in enzyme activity is
15 not due to loss of plasmid sequences, since dot blots reveal the retention of plasmid DNA throughout the larval period. The peak of β -galactosidase activity apparently occurs between the transition from trochophore to veliger -- a point of maximal cell
20 division. Since β -actin levels are positively correlated with cell division, it may be that the *Drosophila* actin promoter is acting in a developmentally correct manner.

The data also demonstrate that the vertebrate
25 retroviral promoter CMV does not seem to be active. Similar results were obtained with the RSV promoter.

To test whether plasmid DNA was retained and expressed post-settlement, approximately 6,000 eggs were electroporated using pMK18 DNA from which we
30 subsequently obtained approximately 200 juveniles. The juveniles were sampled at three, six, and nine months of age (Example 3). A typical dot blot from three-months-old juveniles is shown in Figure 2.

Of the nine animals tested, all retained DNA and,
35 of these, six showed significant levels of β -galactosidase expression (Table 1; assayed essentially as described in Example 4).

TABLE 1

**B-GALACTOSIDE ACTIVITY IN CONTROL
AND EXPERIMENTAL JUVENILE ABALONE**

5

10

15

20

25

30

35

SAMPLE	β -GALACTOSIDASE ACTIVITY*
control 1	6.2
control 2	6.8
control 3	7.4
control 4	7.0
control 5	6.5
control 6	6.0
control 7	6.3
control 8	6.7
control 9	7.3
control 10	8.0
transgenic 1	19.2
transgenic 2	12.0
transgenic 3	25.0
transgenic 4	12.6
transgenic 5	14.5
transgenic 6	7.8
transgenic 7	12.8
transgenic 8	8.4
transgenic 9	14.0
transgenic 10	16.0

40

* β -galactosidase activity is defined as fluorescence at 450 nm/20 min/mg DNA. The activity is the average of two determinations with an error of 1 to 2%.

Similar results were obtained from six- and nine-months old juvenile abalone. Although plasmid DNA persists in juveniles, it must be integrated into genomic DNA for stable transgenic lines to be established. DNA hybridization analysis of uncut genomic DNA revealed that the plasmid sequences were high molecular weight DNA. Such high molecular weight could be due to concatenation, or to concatenation and integration.

To distinguish between these possibilities, genomic DNA was cut with *HindIII* which cuts asymmetrically in the *EcoRI* linearized plasmid used for electroporation (Example 3, Figure 3A). The DNA was analyzed by hybridization with a 200 bp fragment of pMK18 (Figure 3A).

The results of the hybridization analysis were as follows. A strong 8 kb signal, corresponding to two of the three possible types of concatenes, was observed in all genomic DNA samples. A faint approximately 16 kb signal, corresponding to the third type of concatenate, was observed in some of the blots. These results suggest that most of the concatenes may be head-to-tail multimers, as has been observed in fish (Stuart, et al., 1988; Chong and Vielkind, 1989).

Junction fragments were observed approximately 70% of the time, suggesting an extremely high degree of integration. An autoradiogram showing both integrated and un-integrated DNA is shown in Figure 3B (Example 3).

Although the ACT5-C promoter functions in both larvae and juvenile abalone, it appears to do so at only about 5 to 10% efficiency relative to its expression in *Drosophila* S2 cells. Development of more efficient mollusk expression vectors is described below.

Transgenic abalone carrying the coho salmon Growth Hormone (csGH) gene (Gonzalez-Villansenor, et al.)

under the regulation of the ACT5-C promoter have also been constructed. The sequence of the csGH gene is presented as SEQ ID NO:1. The vector containing the csGH gene under ACT5-C control was designated pLH2.

5 The weight distributions of transgenic abalone, carrying the pLH2 vector, relative to control (wild type) abalone were determined. Figure 6 shows the result of one such analysis. The data in the figure demonstrate that the transgenic abalone have a wider
10 weight distribution with a higher mean weight than the non-transgenic controls. These results demonstrate the efficacy of generating transgenic mollusks having enhanced growth properties.

The production of gynogens and triploids can be
15 accomplished by chemical induction of polyploidy, in particular, triploids and tetraploids. Chemical induction can be carried out by treatment with cytochalasin B at a specific phase of the organism's life cycle, such as at meiosis I or meiosis II. In the
20 method, a fertilized abalone egg is provided. The fertilized egg is typically a diploid egg, but may be a different ploidy, such as tetraploid.

The fertilized egg is then treated with a concentration of cytochalasin B effective to induce
25 polyploidy. This concentration is dependent on the type of egg being treated. Effective concentration can be determined empirically. For abalone, the preferred concentration range of cytochalasin B is about 0.1 mg/l to 1 mg/l.

30 The treated egg is then allowed to develop into a polyploid organism. If the fertilized egg is diploid, the resulting polyploid organism is typically triploid or tetraploid.

Treatment with cytochalasin B is typically carried
35 out to block Meiosis I, Meiosis II, or both Meiosis I and II. In a preferred embodiment, such treating results in a greater than 70% inhibition of polar body

formation. Such treatment also provides a method for enhancement of growth of abalone since polyploid organisms typically have enhanced growth properties relative to the same organisms having a normal complement of chromosomes (usually diploid).

Gynogens permit selfing within one generation and provide a mechanism to rapidly homozygose transgenics, as well as expedite more classical breeding approaches. For example, gynogens are used on the F1 to homozygose transgenes -- the F2 are then be made sterile by producing triploids.

Furthermore, triploids (which comprise one component in the production of gynogens) allow production of sterile seed stock, thereby mitigating against environmental concerns over genetically engineered organisms.

III. DEVELOPMENT OF SHELLFISH VECTORS

The present invention also relates to the development of "all abalone" or "all mollusc" expression vectors. Inducible promoters, such as, metallothionein and heat shock promoters (as previously used in fish) can be induced by external stimuli. However, such inducible promoters are not realistically adaptable to large-scale commercial production.

Grow out of abalone occurs in tanks with continuously flowing seawater. It would not be cost-effective nor environmentally prudent to attempt to regulate water temperature or chemical composition on the scale which industrial production demands.

A. ISOLATION OF AN ABALONE β -ACTIN PROMOTER

Experiments performed in support of the present invention are directed to the construction of an abalone expression vectors using the β -actin promoter. This promoter was selected based on two considerations. First, β -actin is expressed in high levels in a number

of adult tissues (Fryberg, et al., 1983). Second, it is possible to modulate β -actin promoter activity by constructing vectors with differing combinations of elements responsible for expression (Liu, et al., 5 1990a; Liu, et al., 1990c). This property is important for expression of some proteins, such as growth hormone where the response of an organism is dependent upon the level of circulating hormone. In the case of growth hormone (GH), organismal growth is proportional to 10 hormone concentration up to a certain optimum, above which it has either no or even slightly inhibitory effects (Agellon, et al., 1988; Moriyama, 1992).

The actin genes are a multigene family (Vanderkerckhove and Weber, 1978a, 1978b). Because the 15 genes are highly conserved, it is not possible to design either probes or primers which distinguish β -actins from α - or γ -actins. In contrast, the 3' untranslated regions do not show extensive homology (Fryberg, et al., 1983; Liu, et al., 1990c) and can be 20 used to identify a specific actin DNA sequence.

To isolate the abalone β -actin gene, a portion of the coding region of the gene was first isolated by polymerase chain reaction amplification (Example 5A). Using a set of degenerate primers for invertebrate 25 actin, an approximately 400 bp fragment within the coding region of the abalone β -actin gene was isolated (Example 5A, Figures 5A, 5B and 8A).

From the approximately 400 bp sequence, abalone β -actin sequence specific primers are synthesized. Using 30 these primers, both the three and five prime ends of the gene are isolated using the PCR rapid amplification of cDNA ends (PCR-RACE) reaction (Frohman, 1988, 1990).

After isolation of the 5' and 3' ends, the sequences are determined. Oligonucleotide probes 35 specific to the 5' and 3' untranslated ends of the gene are synthesized. These oligonucleotides are used as hybridization probes against abalone genomic DNA clones

carried in lambda-gt10 (Stratagene, La Jolla CA). Positively hybridizing clones are identified and subject to restriction endonuclease cleavage mapping. Cleavage fragments are hybridized with the

5 oligonucleotides to identify appropriately sized restriction fragments containing the actin gene and its promoter, as well as 3' and 5' untranslated regions.

The actin gene-containing restriction fragment is cloned by construction of a size-selected library using
10 standard techniques (Sambrook, et al., 1989). The DNA sequence of the entire actin insert is then determined.

Sequences comprising a 5' region of the abalone actin gene, including 5' non-translated sequences have been determined (Example 5B). These sequences are
15 shown in Figure 9 (SEQ ID NO:5). Figure 10 presents a schematic representation of the region of the actin gene that has been sequenced. Transient expression assays (Example 5B, Table 2) demonstrate that the actin gene promoter is functional.

20 The abalone β -actin gene can be used to construct expression vectors (Example 5C). In one embodiment, the abalone actin promoter sequences can be used to construct vectors useful for the transformation of abalone, for example, where a growth hormone gene is
25 placed under its control.

Promoters from other suitable mollusk genes (for example, hexokinase, phosphoglycerate kinase, pyruvate kinase) can be isolated following the procedures essentially as described herein for β -actin.

30

B. CONSTRUCTION OF EXPRESSION VECTORS

Actin promoter specific motifs are identified by comparison with the other actin promoters. Similar comparisons can be made for other isolated abalone
35 genes. Promoter regions and other 5' and 3' functional regions are identified by deletion mapping (Example 5B). Deletions are sequenced and the end-points,

relative to the entire actin gene clone, are determined. Plasmids are constructed containing various proportions of the promoter and the 5' and 3' untranslated regions.

- 5 Polylinker sites are typically inserted between 5' and 3' untranslated gene regulatory regions for rapid cloning. Polylinkers usually containing a number of unique restriction enzyme endonuclease sites, e.g., as in the polylinker of pUC18 (Clontech, Palo Alto CA)).
- 10 Expression vector DNA uptake and DNA integration into fertilized eggs is determined as described in Examples 2 and 3.

- Actin gene expression cassettes (i.e., 5'/3' actin sequences flanking a polylinker) are typically cloned
- 15 into shuttle vectors for ease of manipulation and isolation of large quantities of vector DNA. A number of such shuttle vectors are commercially available (Clontech, Palo Alto, CA; Stratagene, La Jolla, CA). Shuttle vectors typically contain an origin of replica-
- 20 tion (for plasmid propagation in a selected host, e.g., the origin of replication can be colE1-type) and a selectable marker gene which allows selection in the host cells (e.g., for bacteria, the β -lactamase gene (Amp^R)).

25

C. DETERMINATION OF LEVELS OF EXPRESSION

- Levels of gene expression using the expression vectors of the present invention, are determined by generation of transgenic abalone and characterization
- 30 of expression of the heterologous DNA in living larvae and juveniles. A number of reporter genes are useful for the quantitation of gene expression, including, β -galactosidase, chloramphenicol acetyltransferase (CAT), and luciferase (de Wet, et al., 1987; Gibbs, et al.,
- 35 1991) genes. Typically, the reporter gene is inserted into the expression cassette (e.g., the actin gene expression cassette) as an in-frame fusion.

Levels of gene expression are quantitated by standard enzymatic assays for the detection of the selected reporter gene (e.g., CAT enzyme assay systems, Promega, Madison WI).

- 5 Further, quantitation of the levels of expression is performed using RNA hybridization analysis (Ausubel, et al.; Sambrook, et al.) and comparing the levels of the endogenous gene RNA (e.g., β -actin mRNA) to the levels of reporter gene RNA (e.g., luciferase mRNA).

10

IV. ISOLATION OF SHELLFISH GENES AFFECTING GROWTH

A. GROWTH HORMONE GENES

- Insertion of growth hormone (GH) genes has resulted in increased growth rates in a number of commercially important aquatic organisms, such as loach (*Misgurnus anguillicaudatus*) (Zhu, et al., 1986), carp (*Cyprinus carpio*) (Zhang, et al., 1990), Atlantic salmon (*Salmo salar*) (Rokones, et al., 1989; Du, et al., 1992), rainbow trout (*Onorhynchus mydiss*) (Guyomard, et al., 1989), northern pike (*Esox lucius*) and walleye (*Stizostedion vitreum*) (Moav, et al., 1992a). Transgenic fish are typically one to three times larger than their non-transgenic siblings.

- Commercially important shellfish -- abalone and oysters, respond to exogenous GH (Morse, et al., 1981, 1984). Incubation of abalone larvae at metamorphosis with human GH resulted in approximately a 10% increase in shell length after four days. Recently, Moriyama (1992) has shown that either injection or immersion of juvenile abalone with recombinant salmon hormone results in a two-to-three-fold weight increase.

- Similar results have been reported by Paynter and Chen (1991) for the eastern oyster (*Crassostrea virginica*). The positive effects of GH on these shellfish most likely reflect the presence of complex hormonal systems in the primitive mollusks (Joosse and Garaerts, 1983). Consistent with this interpretation,

Moriyama and his colleagues have isolated and partially purified a growth hormone-like peptide from abalone, and this peptide also stimulates growth (Moriyama, et al., 1989, 1992).

5 The present invention describes recombinant vectors and methods by which genes may be introduced that affect mollusk growth. Following the method of the present invention, the abalone GH gene is cloned in, for example, the actin cassette expression vector
10 such that the resulting protein expression product is an actin/GH fusion protein. Alternatively, the actin regulatory sequences are used to replace the GH regulatory sequences, thus placing the GH gene under the transcriptional and translational control of the
15 actin gene regulatory sequences.

 Further, the methods of the present invention may be used to modify endogenous copies of the GH gene by deleting normal GH gene regulatory sequences and replacing them with regulatory sequences conferring
20 higher levels of expression (i.e., gene replacement).

B. OTHER POTENTIALLY USEFUL GENES

 In addition to the use of abalone growth hormone gene to enhance the growth rates and ultimate sizes of transgenic abalone, the Insulin-like Growth Factor (IGF
25 1) gene may also be used to enhance growth via its positive regulation of GH (Sara and Hall, 1990). The IGF 1 gene has recently been isolated from oysters. IGF 1-like sequences from a variety of organisms can be
30 used to generate degenerate primers for the isolation of the abalone homologue of the IGF 1 gene (as described herein for isolation of the abalone β -actin gene).

35 V. UTILITY

 The present invention includes a method of transforming members of the phylum mollusca. This phylum

includes the class Gastropoda, which includes abalones.

A. VECTORS AND STRAIN VARIANTS

5 The present invention provides vectors suitable
for the transformation of mollusks. Such vectors can
be sold individually or in kits for use in the
transfection and transformation methods of the present
invention. Kits may also include buffers useful for
10 transformation.

The vectors and methods of the present invention
can be used to generate transgenic aquatic organisms,
such as, transgenic abalone. The vectors and methods
can be used to introduce heterologous DNA or,
15 alternatively, to modify endogenous genes by
recombinant genetic methods. Such transgenic organisms
may be manipulated to have enhanced growth rates as
described above. In addition to increased growth,
strains may be engineered that have other properties
20 such as disease resistance, shell and/or meat
coloration, meat texture, and taste. This technology
can be extended to other commercially important
mollusks as well as abalone.

25 B. GENETIC ANALYSIS

The transfection method of the present invention
complements more classical genetic approaches. The
efficiency of gene expression described herein makes
possible detailed studies on the expression of genes
30 important to the processes of growth and organismal
development. Further, the transformed organisms of the
present invention provide means for screening compounds
(typically by employing the effects of such compounds
on the expression of reporter genes, e.g., a reporter
35 gene under the control of the GH promoter) effective to
interfere with or promote such processes. The
transgenic mollusks of the present invention are also

vehicles for the expression of heterologous proteins encoded by DNA introduced by transfection.

The vectors and methods of the present invention also provide the means for recombinant genetic
5 manipulations of mollusks, including gene replacements and gene knock-outs.

While preferred embodiments, uses, and methods of practicing the present invention have been described in
10 detail, it will be appreciated that various other uses, formulations, and methods of practice as indicated herein are within the contemplation of the present invention.

15 MATERIALS AND METHODS

E. coli DNA polymerase I (Klenow fragment) was obtained from Boehringer Mannheim Biochemicals (BMB) (Indianapolis, IN). T4 DNA ligase and T4 DNA
20 polymerase were obtained from New England Biolabs (Beverly, MA); Nitrocellulose filters were obtained from Schleicher and Schuell (Keene, NH).

Synthetic oligonucleotide linkers and primers were prepared using commercially available automated oligonucleotide synthesizers. Alternatively, custom
25 designed synthetic oligonucleotides may be purchased, for example, from Synthetic Genetics (San Diego, CA). cDNA synthesis kit and random priming labeling kits were obtained from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN).

30 Oligonucleotide sequences encoding peptides can be either synthesized directly by standard methods of oligonucleotide synthesis, or, in the case of large coding sequences, synthesized by a series of cloning steps involving a tandem array of multiple
35 oligonucleotide fragments corresponding to the coding sequence (Crea; Yoshio, et al.; Eaton, et al.). Oligonucleotide coding sequences can be expressed by

standard recombinant procedures (Maniatis, et al.; Ausubel, et al.).

Standard molecular biology and cloning techniques were performed essentially as previously described in
5 Ausubel, et al., Sambrook, et al., and Maniatis, et al.

Polymerase chain reactions were carried out essentially per the manufacturer's instructions. Polymerase chain reaction methods are generally described in Kawasaki, Mullis, and Mullis, et al.

10 Fertilized eggs were obtained from Pacific Mariculture Inc., 5515 Coast Road, Santa Cruz, CA 95060. Other sources for fertilized eggs are as follows: The Abalone Farm Inc., P.O. Box 136, Cayocos, CA 93430; and Ab Lab, 560 Center Drive, Port Hueneme,
15 CA 93043-4328.

EXAMPLE 1

CONSTRUCTION OF PLASMIDS

The plasmids pMK18 and pLH2 were constructed from
20 pMK26 (Figure 7; Koelle, et al., 1991, pMK26 = pAct/SV40/BS). Plasmid pMK26 contains the *Drosophila melanogaster* ACT5-C promoter, a β -actin promoter. This promoter is expressed throughout development and in most adult tissues (Fryberg, et al., 1983). Both
25 vectors were constructed from pMK26 modified as follows: pMK26 was partially digested with *EcoRI* and the *EcoRI* site, next to the *KpnI* site in pMK26 (Figure 7), was filled in using Klenow and dNTPs (Ausubel, et al.; Maniatis, et al.). The resulting plasmid was
30 recircularized by blunt end ligation and a modified pMK26 having a single *EcoRI* site was identified by restriction mapping.

pMK 18 was constructed by inserting the 4.8 β -galactosidase ubx cassette of cP bxd6.2 (Irvine, et
35 al., 1991) by blunt end ligation of the fragment into the *SmaI* site of modified-pMK26. For electroporation plasmids were linearized at the unique *EcoRI* site.

For the construction of pLH2, a 1070 KB *HindIII* fragment containing the csGH gene, as well as all of the 5'-untranslated leader and 373 BP of the 3' untranslated region, were obtained from pRSVCSGH (Gonzalez-Villansenor, et al.). The *HindIII* fragment was ligated into the unique *HindIII* site in the modified pMK26 poly linker. This plasmid was linearized with *EcoRI* for electroporation. The DNA sequence of csGH is presented as SEQ ID NO:1. The entire translated sequence of csGH is presented as SEQ ID NO:2.

The pLUC vector was generated as follows. The 2.0 kb *XhoI/StyI* fragment of pXP2 (Nordeen, Biotechniques 6:454-457, 1988) was isolated which contains the luciferase gene and SV40 regulatory sequences. This fragment was cloned into *XhoI/StyI* digested pBLCAT6 (Boshart, et al., Gene 110:129-130, 1992) to generate a promoter-less luciferase-containing vector.

The pCMVtkLUC vector contained the luciferase gene under the control of an HSV thymidine kinase promoter with a CMV enhancer.

EXAMPLE 2

INTRODUCTION OF DNA INTO ABALONE

For introduction of DNA, 200 μ l of fertilized abalone eggs, at a concentration of 4000-6000 eggs/200 μ l, were added to each Baekon 2000 electroporater cuvette. Each cuvette contained 100 μ l of linearized plasmid DNA, at a concentration of 2 mg/ml, and 400 μ l of artificial seawater.

A typical artificial sea water is composed as follows: 24.72 g/l NaCl, 0.67 g/l KCl, 1.36 g/l $\text{CaCl}_2 \cdot 2(\text{H}_2\text{O})$, 4.66 g/l $\text{MgCl}_2 \cdot 4(\text{H}_2\text{O})$, 6.29 g/l $\text{MgSO}_4 \cdot 7(\text{H}_2\text{O})$, 0.18 g/l sodium carbonate, pH 7.8.

Electroporation condition were as follows: 10KV, 6 cycles, pulse time:160uS, and burst time 1.6 seconds. Following electroporation, the eggs were put into 1

liter of sea water containing 100 µg/l each penicillin and streptomycin (pen/strep; Life Technologies, Gaithersburg MD). The eggs/larvae were cultured at 14°C with aeration. The seawater/pen/ strep were changed every day.

EXAMPLE 3

GENOMIC DNA HYBRIDIZATION ANALYSIS OF TRANSGENIC ABALONE

10 A. DNA UPTAKE AND RETENTION

Abalone eggs, transfected with the vectors described above, were evaluated for the presence of transfecting DNA. DNA was extracted from electroporated eggs two hours (first cleavage division) and twenty-four hours (trochophore larvae) post-fertilization (Hahn, 1989). The first time point monitored DNA uptake, while the second monitored DNA retention.

For each time point a pool of 5 eggs or larvae were ground in 10 µl of TE (Maniatis, et al.) in an "EPPENDORF" microcentrifuge tube using a homogenizer. Debris was cleared and the nucleic acid precipitated. Resuspended DNA samples were then transferred to nitrocellulose using a dot blot capture system (Ausubel, et al.; Schleicher and Schuell).

Exemplary results of such a dot blot analysis is presented in Figure 1. This figure demonstrates uptake and retention of plasmid DNA into electroporated abalone eggs. The DNA bound to the nitrocellulose filters was hybridized with radiolabeled plasmid pMK18 DNA (random primer, Boehringer-Mannheim, Indianapolis IN). In Figure 1, the first two slots from the left, in the bottom row of the two hour samples, are DNA extracted from non-electroporated eggs. The standards are presented in the top panel of the figure, from left to right, 600, 300, 100, 60 and 30 picograms of pMK18 DNA.

The data obtained in this manner suggested that DNA is taken up and retained in approximately 80-100% of all electroporated eggs.

5 B. RETENTION OF TRANSFECTED DNA

Abalone transfected with the pMK18 vector were grown. DNA was extracted from three-month-old juveniles and analyzed by dot blots using radiolabeled plasmid pMK18 DNA. Figure 2 shows the dot blot
10 hybridization data for the transgenic abalone and untransformed controls. Concentration standards are (from left to right) 600, 400, 100, 60, 30, 10, 6 and 3 picograms of pMK18 DNA.

The results in Figure 2 demonstrate the retention
15 of electroporated DNA in three-month-old juvenile abalone.

 C. DNA HYBRIDIZATION ANALYSIS OF 3-MONTH OLD JUVENILE
 TRANSGENIC ABALONE

20 The DNA samples isolated from 3 month old juvenile transgenic abalone (above) were loaded onto agarose gels, size fractionated and transferred to nitrocellulose filters (Ausubel, et al.; Sambrook, et al.). The filters were hybridized with radioactively
25 labeled pMK18. Autoradiograms of these filters demonstrated that the pMK18 homologous sequences were present in high molecular weight DNA. The results are presented in Figure 3B. In the figure, the DNA samples in the two lanes were isolated from two different
30 animals. The DNA in the left hand panel is integrated. The DNA in the right hand panel has not integrated.

To distinguish between concatemers and integration of pMK18, the genomic DNA samples were digested with the restriction endonuclease *HindIII*. This restriction
35 endonuclease cuts asymmetrically in the *EcoRI* linearized plasmid that was used for electroporation (see Figure 3A). The DNA on the nitrocellulose filters was hybridized with a 200 bp polymerase chain reaction

(Perkin-Elmer/Cetus, Norwalk CT) amplified fragment from an 8 kb *HindIII*/*EcoRI* fragment of pMK18 (see Figure 3A).

5 A strong 8 kb signal was observed that corresponded to two of the three possible types of concatenates (Figure 3B). The 8 kb signal was observed in all genomic DNA samples indicating the presence of concatenates in each sample.

10 An approximately 16 kb signal was also observed in some of the DNA samples. The 16 kb signal corresponded to the third type of concatenate (Figure 3A). These results suggest that most of the concatenates may be head-to-tail multimers.

15 Junction fragments were observed in approximately 70% of the DNA samples derived from transgenic abalone (Figure 3B, e.g., signals appearing at molecular weights of less than 8 kb). This result suggests an extremely high degree of integration.

20

EXAMPLE 4

ANALYSIS OF GENE EXPRESSION IN TRANSGENIC ABALONE

The vector pMK18 contained an expression cassette for β -galactosidase. Transgenic abalone bearing the vector were assayed for the expression of β -galactosidase over time.

25 Pools of fifty larvae were extracted at various intervals during the period of larval development and the levels of β -galactosidase determined using the fluorescent substrate 4-methylumbelliferyl- β -D-galactoside (Sigma Chemical Co., St. Louis, MO) essentially as previously described by Koelle, et al. (1991).

30 Figure 4 presents the data from exemplary fluorescence experiments for the expression of β -galactosidase in electroporated larvae. Fluorescence units are on the Y-axis and time in days (post

fertilization) is presented of the X-axis. Enzyme activity is expressed in arbitrary fluorescence units.

The data presented in Figure 4 are the average 5 separate electroporation experiments for plasmids pMK18 and two separate experiments for control plasmid CMVLac. CMVLac is a vector carrying the cytomegalovirus promoter adjacent the β -galactosidase gene (e.g., "pCMV β " Clontech, Palo Alto CA). The standard errors have not been computed; however, the variation among experiments was less than 5%.

The data suggest that β -galactosidase is expressed when pMK18 (β -actin promoter) was employed. The decline in enzyme activity is not due to loss of plasmid sequences, since dot blots reveal the retention of plasmid DNA throughout the larval period.

The vertebrate retroviral promoter CMV does not seem to be active in transgenic abalone. Similar results were obtained with the RSV promoter.

20

EXAMPLE 5

IDENTIFICATION AND ISOLATION OF ABALONE ACTIN GENE AND CONSTRUCTION OF MOLLUSK EXPRESSION VECTORS

25 A. Isolation of an Approximately 400 Base Pair Fragment of the Abalone Actin Gene.

A set of degenerate primers for invertebrate actin (based on the "GENBANK" sequences for *D. Melanogaster* (5CX, 8F, 87E), *B. Moryi* (A1, A2, A3) actin genes) was designed. The sequences of these primers are presented as SEQ ID NO:3 and SEQ ID NO:4. These primers amplify an approximately 400 bp fragment within the target coding regions (Figure 5A). A schematic of the isolation of this approximately 400 bp fragment is presented in Figure 8A.

35 RNA was isolated from abalone ovary tissue (R.A. Cox I Methods in Enzymology, L. Grossman and K. Moldave, Eds., Vol 12, partB. pp. 120-129, Academic

press, Orlando, FL, (1988); "RNAZOL" kit from Tel-Test, Inc. Friendswood, Texas).

cDNA was synthesized from 5 μ g of total ovary RNA, in a final volume of 20 μ l, using 10 μ l of reverse transcriptase (Invitrogen, San Diego, CA). One μ l of each cDNA sample was used in a 100 μ l polymerase chain reaction (PCR) including the primers at 20 μ M. Polymerase chain reaction conditions and protocols were generally similar to those found in commercially available kits (Perkin-Elmer, Norwalk, CT).

Amplified products were resolved on the basis of size using electrophoresis. After amplification, approximately 7% of each reaction product mixture was separated by electrophoresis in 1% agarose gels (FMC Bioproducts, Rockport, ME). Gels were stained with ethidium bromide for visualization under UV illumination.

The results of one such analysis are presented in Figure 5B. The first lane of the figure shows the amplification products resulting from amplification utilizing the degenerate actin primer set and DNA from ovary. The second lane shows the amplification products resulting from amplification utilizing the degenerate actin primer set and total abalone ovary RNA. The expected amplification product of approximately 400 bp was observed in the second lane.

The sequence of this 400 bp fragment was confirmed by standard DNA sequencing methods.

B. Isolation of the Abalone Actin Promoter Sequences.

Abalone actin gene sequence specific primers were derived from the approximately 400 base pair sequence described above. A primer was selected to be complementary to the DNA strand corresponding to the actin protein coding sequence (Figure 8B).

An abalone genomic DNA library was generated in lambda gt 10 (Ausubel, et al.; Stratagene). This

library was employed as the DNA substrate in polymerase chain reaction amplifications using the actin specific primer just described as the first primer and a set of random primers (BMB, Indianapolis, IN) as the second
5 primer (Figure 8B).

Genomic walking experiments lead to the isolation of the genomic coding sequences of the abalone actin gene. Figure 9 (SEQ ID NO:5) presents a partial sequence of 1540 base pairs representing a 5' coding
10 region of the actin gene and accompanying 5' non-coding sequences. Sequencing and RNase protection assays were performed in order to map the gene's intron positions and the transcription start point. The structure of the abalone gene corresponding to the sequence
15 presented in Figure 9 is diagrammatically represented in Figure 10. Promoter motifs (e.g., the TATA box) and the promoter region are illustrated in the figure, as are two exons and an intron of the actin protein coding region.

20 The two expression vector constructs were created with the actin sequences. First, essentially the entire clone was introduced into the multiple cloning site of the vector pLUC (Figure 11). This vector was designated pABA1600LUC. A second vector was created
25 having approximately the first 800 bp of SEQ ID NO:5 introduced into the multiple cloning site of pLUC (designated pABA800LUC). The reporter gene in these vector constructs was the luciferase gene (LUC).

pABA1600LUC, pABA800LUC, pLUC (negative control,
30 Example 1) and pCMVtkLUC (positive control, Example 1) were transfected into Human Embryonic Kidney Cell Line ATK293 following standard calcium phosphate transfection procedures.

Transient expression assays using these
35 transformed cell lines were performed. The activity of the abalone actin promoter in the transfection assays was determined as fg Luciferase per U galactosidase.

Percent activity was determined relative to the negative control (cells transformed with pLUC alone). The results of this analysis are presented in Table 2.

Table 2

5

	fg Luciferase/ U galactosidase	% Activity
pLUC	7	-
pcMvtkLUC	382	311
pABA1600LUC	47	38
pABA800LUC	123	100

10

These results demonstrate the ability of the cloned actin sequences to provide promoter function in expression vector constructs.

15

C. Generation of Abalone Actin Promoter-Based Vectors.

For ease of manipulation, the β -actin sequences are cloned into a shuttle vector. For example, the "SK+ BLUESCRIPT" vector provided sequences allowing the replication and selection of the vector constructs in a bacterial host. Other known bacterial vector systems (e.g., Clontech, Palo Alto CA) can be used in this capacity as well. Further, yeast vectors can be used in the practice of the present invention (e.g., Hitzeman, et al.; Rutter, et al.; Oeda, et al.). The yeast transformation host is typically *Saccharomyces cerevisiae*, however, other yeast suitable for transformation can be used as well (e.g., *Schizosaccharomyces pombe*).

30

For generating vectors for the expression of heterologous DNA (DNA not originally derived from the organism being transformed), transcriptional and translational regulatory sequences (including initiation and termination sequences) are typically

35

obtained from 5' and 3' non-coding regions of genes (as described above for β -actin from abalone).

To further characterize specific active promoter sequences, the 5' non-coding sequences, containing
5 actin gene promoter sequences identified by sequence comparisons (Figure 10), and contiguous 5' coding sequences are fused in-frame to reporter protein coding sequences, such as β -galactosidase, luciferase or chloramphenicol acetyltransferase (CAT) (Gorman).

10 A series of plasmids, containing the β -actin 5'-end and reporter gene, are constructed by Exo III digestion of the 5' distal end of the promoter containing region (Hoheisel and Pohl, 1986; Henikoff, 1987). The deletion series is transfected into
15 abalone eggs as described above and the eggs assayed for the expression of the reporter gene. Plasmids expressing the reporter gene are sequenced to determine the endpoints of the deletions.

Appropriate expression plasmids are constructed
20 containing various proportions of the actin promoter and the 5' and 3' untranslated regions. Unique restriction sites will be inserted between the 5' and 3' untranslated regions for rapid cloning. DNA uptake and integration using this vector is
25 determined by dot blots and DNA hybridization assays, as described above.

While the invention has been described with reference to specific methods and embodiments, it
30 will be appreciated that various modifications and changes may be made without departing from the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: The Board of Trustees of the Leland
Stanford Junior University
- (B) ADDRESS:
- (C) CITY: Stanford
- (D) STATE: CA
- (E) COUNTRY: USA
- (F) POSTAL CODE: 94305

(ii) TITLE OF INVENTION: GENETIC ENGINEERING OF
MOLLUSKS

(iii) NUMBER OF SEQUENCES: 5

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Dehlinger & Associates
- (B) STREET: P.O. Box 60850
- (C) CITY: Palo Alto
- (D) STATE: CA
- (E) COUNTRY: USA
- (F) ZIP: 94306-0850

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/286,872
- (B) FILING DATE: 05-AUG-1994

(viii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/192,272
- (B) FILING DATE: 04-FEB-1994

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/191,494
- (B) FILING DATE: 04-FEB-1994

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Fabian, Gary R.
- (B) REGISTRATION NUMBER: 33,875
- (C) REFERENCE/DOCKET NUMBER: 8600-0144.41

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (415) 324-0880
- (B) TELEFAX: (415) 324-0960

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1201 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Coho Salmon Growth Hormone Gene

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 65..697
- (D) OTHER INFORMATION: /note= "Growth Hormone Precursor"

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 65..130
- (D) OTHER INFORMATION: /note= "growth hormone signal peptide"

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 131..697
- (D) OTHER INFORMATION: /note= "Growth Hormone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TACATACTCA ACCGACCACC GCACTTTCAA GTTAAGTAAC CATCCTTGGC AATTAAGAGT	60
AAAAATGGGA CAAGTGTTTC TGCTGATGCC AGTCTTACTG GTCAGTTGTT TCCTGAGTCA	120
AGGGGCAGCG ATAGAAAACC AACGGCTCTT CAACATCGCG GTCAGTCGGG TGCAACATCT	180
CCACCTATTG GCTCAGAAAA TGTTCAATGA CTTTGACGGT ACCCTGTTGC CTGATGAACG	240
CAGACAGCTG AACAGATAT TCCTGCTGGA CTTCTGTAAC TCTGACTCCA TCGTGAGCCC	300
AGTCGACAAG CACGAGACTC AGAAGAGTTC AGTCCTGAAG CTGCTCCATA TTTCTTTCCG	360
TCTGATTGAA TCCTGGGAGT ACCCTAGCCA GACCCTGATC ATCTCCAACA GCCTATTGGT	420
CGGAAACGCC AACCAGATCT CTGAGAAGCT CAGCGACCTC AAAGTGGGCA TCAACCTGCT	480
CATCATGGGG AGCCAGGATG GCCTACTGAG CCTGGATGAC AATGACTCTC AGCAGCTGCC	540
CCGCTACGGG AACTACTACC AGAACCCGGG GGGCGACGGA AACGTCAGGA GGAACACGA	600
GTTGTTGGCT TGCTTCAAGA AGGACATGCA CAAGGTCGAG ACCTACCTGA CCGTCGCCAA	660
GTGCAGGAAG TCACTGGAGG CCAACTGCAC TCTGTAGACG TGGGCTGGAG AGGCAGCCAG	720
CAAGAGCCTG TCTCCAGGGT TTGGTTTCCC AGATACAGAT TAGGCCTTGC CCTGCACTGA	780
GGTGCATTTT CAATTGAGAT TCTCCATTGA ACATGCTTTT CAGTCTAGAG TAATTTTATT	840
TTGGATCTGG TAGAGCCTGA CTCCAGGGGT TTTCAGGCAT TTGCACTTTT TTTCTCTGAA	900
ATCAACAACA AACTTTTCTA TATTGACTCT ATCACTCTGA GCTACCATTG ATTAGTACAT	960
TTATAGAAAA GGTTATTAAA TGTCTTATTT AGATATATGG TTCATGGCGG TGCTACTGTT	1020
TATGCATACG TTAATATTTA GGGGTGAAAT GGGAACTTGT AGAGCTCCAA GCTTTTGGAT	1080
AATATATTTT AGAGTAATTT CCTTTAAGTA TTTTCATTCC TTAATCTTAT TGTTTGAAAC	1140
TAATAGTGAT TCATGTTTCA ATAAAGATGT TCTTCTCTGC AGCAAAAAAA AAAAAAAA	1200
A	1201

38

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 210 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Coho Salmon Growth Hormone

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Gly	Gln	Val	Phe	Leu	Leu	Met	Pro	Val	Leu	Leu	Val	Ser	Cys	Phe
1					5				10					15	
Leu	Ser	Gln	Gly	Ala	Ala	Ile	Glu	Asn	Gln	Arg	Leu	Phe	Asn	Ile	Ala
			20					25					30		
Val	Ser	Arg	Val	Gln	His	Leu	His	Leu	Leu	Ala	Gln	Lys	Met	Phe	Asn
		35					40					45			
Asp	Phe	Asp	Gly	Thr	Leu	Leu	Pro	Asp	Glu	Arg	Arg	Gln	Leu	Asn	Lys
	50					55					60				
Ile	Phe	Leu	Leu	Asp	Phe	Cys	Asn	Ser	Asp	Ser	Ile	Val	Ser	Pro	Val
65					70					75				80	
Asp	Lys	His	Glu	Thr	Gln	Lys	Ser	Ser	Val	Leu	Lys	Leu	Leu	His	Ile
			85						90					95	
Ser	Phe	Arg	Leu	Ile	Glu	Ser	Trp	Glu	Tyr	Pro	Ser	Gln	Thr	Leu	Ile
			100					105					110		
Ile	Ser	Asn	Ser	Leu	Leu	Val	Gly	Asn	Ala	Asn	Gln	Ile	Ser	Glu	Lys
		115						120					125		
Leu	Ser	Asp	Leu	Lys	Val	Gly	Ile	Asn	Leu	Leu	Ile	Met	Gly	Ser	Gln
		130						135					140		

39

[illegible]

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Actin 5' Primer

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "Where N is C or T"

(1x) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 24
(D) OTHER INFORMATION: /note= "Where N is C or T"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 27

(D) OTHER INFORMATION: /note= "Where N is G or A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAGAAGATGA CNCAGATCAT GTTNGANAC

29

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Actin 3' Primer

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "Where N is G or Inosine"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "Where N is C or G"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 16
- (D) OTHER INFORMATION: /note= "Where N is G or Inosine"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 17
- (D) OTHER INFORMATION: /note= "Where N is G or A"

(ix) FEATURE:

41

- (A) NAME/KEY: misc_feature
(B) LOCATION: 18
(D) OTHER INFORMATION: /note= "Where N is T or C"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CATNATNGAG TTGTANNNGG TCTCGTGGAT

30

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1540 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: ABALONE ACTIN GENE SEQUENCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGAACAGTGT CAAACATATA TACAAGCTTG ATGGTGAGAA ATATTAGCAT TAATACTGTC	60
ACTTGTGTGTT TAGCATATTA TTTCTGATAT ATAAATACTT AGGAAATTCT ATTTTCTCA	120
TGCAAAAAGC CACTTAACTT CATCAATAAA ATCGTTATCT GCACCTAAGA ATGATCTTCC	180
ATCATCTCTA TGTTGACATA CGTTTTATCA TCCAGATTAT CAATGAAAGT CGAAAAGATT	240
ACAACTCCCT CTGAAATATG AATATTCACA GTTTAGAGGG CAAGTAAAGC CAACACAAC	300
ACTTGCACG GCGAGAACAA GCAATATCAG GGTGTACAT TCTGTACATT CGTTAGATAT	360
TTTACTTCTG GGTCCAATCC TTATTACACA CTGCATTTCT TCCAGGAAGT TTGGATATAA	420
CTTTACAATG CTTTATAACT GATGAGTAGT AAGCGTTGTA TGGATTTTAG AATCTATGCA	480
TTTCCCAATA ATGCTGATAT ATTCATTTAA CTTAATTTAT TACCAGCATC ACATTCTGTC	540

ATTCATGCTC GTCAGCTCGA GAAGCGCTTC CCCATTCTCC GCGCACCATA CCACGTGGCG	600
TTGTCCTTGC TTCGGGAACG GGGGTAGGGG GTACTTACTT CTAGGGGAAA GAGAGATCAG	660
TGCAGATCAC CCCCAGCTGT GACACATTCT TCCACATGTA CACATGAAAG GTTGTTATGC	720
AATATAATAC ATTAGAAGGG TATATTTATT ACAATTACAA TGGTTACGTT TCTATTATTC	780
TCAAACACAA TCTGATTGGT CGCCTACTAA TGGGGTATGT ATAAAAGACG CCTGGGTCAG	840
AACATCGATA TTGCATCCGC TTTCAGTCTT CAGCTGACAC ATCGTCTTTC CCGTTTCTCA	900
CACAGCAACC TACAACCATG GATGATGATG TTGCTGCATT GGTCTGTGAC AACGGCTCCG	960
GCATGTGCAA GGCCGGTTTT GCCGGTGACG ACGCTCCAG AGCTGTCTTC CCCTCCATCG	1020
TCGGCCGTCC TAGACATCAG GTAACACCGT TTATTGTCAC CATGGTAACA TAGAGGTTCA	1080
AGACCTGAAA TATTTAGTTT CGCCTACATT TCGTCTCTGT AGAATACAG ACGTCGTACA	1140
TAATGACAAA TGATTTCTTG TTTCAGGGTG TGATGGTTGG TATGGGTCAG AAAGACAGCT	1200
ACGTGGTGA CGAGGCTCAG TCCAAGAGAG GTATCCTCAC TCTCAAGTAT CCCATCGAGC	1260
ACGGTATCGC CACCAACTGG GACGACATGG AGAAGATCCG GCATCACACC TTCTACAACG	1320
AACTCCGAGT GGCTCCAGAG GAGCACCCTG TCCTYCTGAC AGAGGCTCCC CTCAACCCCA	1380
AGGCCAACCG TGAAGAGATG ACCCAGATCA TGTTCGAGAC CTTCAACTCT CCAGCTATGT	1440
GTGTGGCCAT CCAGGCTGTT CTGTCTCTGT ACGCTTCTGG TCGTACCAG GGTATTGTTC	1500
TGGA CTCTGG TGATGGTGTT ACCCACACTG TTCCCATCTA	1540

IT IS CLAIMED:

1. A transgenic mollusk containing a DNA sequence heterologous to said mollusk.

5

2. A transgenic mollusk of claim 1, where said DNA sequence is integrated at a genomic DNA site of said mollusk.

10

3. A transgenic mollusk of claim 1, where said DNA sequence is extra-chromosomal.

15

4. A transgenic mollusk of claim 1, where said DNA sequence is flanked by regulatory sequences, and where said regulatory sequences are effective to allow expression in said mollusk of said DNA sequence.

20

5. A transgenic mollusk of claim 4, where said regulatory sequences are derived from said mollusk.

6. A transgenic mollusk of claim 5, where said regulatory sequences include promoter sequences derived from an actin gene.

25

7. A transgenic mollusk of claim 6, where said promoter sequences are derived from an abalone actin gene.

30

8. A transgenic mollusk of claim 7, where said promoter is derived from SEQ ID NO:5.

9. A transgenic mollusk of claim 4, where said DNA sequence is flanked by regulatory sequences derived from a *Drosophila melanogaster* gene.

35

10. A transgenic mollusk of claim 9, where said regulatory sequences are derived from the ACT-5

promoter, and said heterologous DNA sequence encodes coho salmon growth hormone.

11. A transgenic mollusk of claim 1, where said
5 heterologous DNA sequence encodes a gene that promotes growth enhancement.

12. A transgenic mollusk of claim 11, where said
10 gene encodes a growth factor or an insulin-like growth factor.

13. A transgenic mollusk of claim 12, where said
gene encodes coho salmon growth hormone.

14. A transgenic mollusk of any of claims 1 to
15 13, where said mollusk is an abalone.

15. A method for enhancing the growth of a
mollusk, comprising
20 culturing a transgenic mollusk, containing a heterologous DNA sequence encoding a protein, where said heterologous DNA sequence (i) is flanked by regulatory elements effective to allow expression of the encoded protein in said mollusk, and (ii) encodes a
25 gene that promotes growth enhancement, where said culturing is under conditions permissive for the expression the protein.

16. A method of claim 15, where said transgenic
30 mollusk is a transgenic mollusk of any of claims 2-14.

17. A method for the recombinant expression of a
protein in a mollusk, comprising
35 culturing a transgenic mollusk, containing a heterologous DNA sequence encoding a protein, where said heterologous DNA sequence is flanked by regulatory elements effective to allow expression of the encoded

protein in said mollusk, where said culturing is under conditions permissive for the expression the protein.

18. A method of claim 17, where said transgenic
5 mollusk is a transgenic mollusk of any of claims 2-14.

19. An expression vector useful for transforma-
tion of a mollusk, comprising
a first DNA sequence flanked by regulatory
10 elements effective to allow expression of the sequence
in said mollusk, wherein said regulatory elements are
derived from a mollusk gene, and
second DNA sequences allowing the propagation of
the vector in a secondary host.

15

20. An expression vector of claim 19, where said
secondary DNA sequences include an origin of replica-
tion and a selectable marker.

20

21. An expression vector of claim 19, where said
secondary host is bacterial.

22. An expression vector of claim 19, wherein
said regulatory elements are derived from a mollusk
25 actin gene.

23. An expression vector of claim 22, wherein
said regulatory elements include promoter sequences
from an abalone actin gene.

30

24. An expression vector of claim 23, where said
promoter sequences are derived from SEQ ID NO:5.

25. An expression vector of claim 19, where said
35 first DNA sequence encodes a growth hormone or insulin-
like growth factor.

26. An expression vector of claim 25, where said growth hormone is coho salmon growth hormone.

5 27. An expression vector of any of claims 19 to 26, where said mollusk is an abalone.

28. A method for transfecting a mollusk, comprising,
10 providing a vector containing a DNA sequence, introducing said vector into said mollusk, and identifying a transfected mollusk based on the presence of said DNA sequence.

15 29. A method of claim 28, where said vector is a vector of any of claims 19 to 26.

30. A method of claim 28, where said transfecting includes integration of the vector at a genomic site.

20 31. The method of claim 28, wherein said introducing is accomplished by electroporation.

25 32. A method of claim 31, where said introducing is accomplished by electroporating said vector into a fertilized mollusk egg.

33. A method of any of claims 28 to 32, where said mollusk is an abalone.

30 34. A duplex DNA fragment containing a DNA sequence encoding a polypeptide, adjacent said DNA sequence a promoter effective to promote transcription of said DNA sequence, where said promoter is an abalone actin gene promoter and said DNA sequence
35 is heterologous to the abalone actin gene promoter.

35. A duplex DNA fragment of claim 34, where the polypeptide promotes growth enhancement and is a growth hormone or insulin-like growth factor.

5 36. A duplex DNA fragment of claim 35, where said growth hormone is coho salmon growth hormone.

37. A method for the production of a polyploid abalone comprising:

- 10 a) providing a fertilized abalone egg,
 b) treating the fertilized egg with cytochalasin B to induce polyploidy,
 c) allowing the treated egg to develop into a polyploid organism.

15

38. A method of claim 37, wherein said treating results in a greater than 70% inhibition of polar body formation.




Fig. 1







Fig. 2

**Fig. 3A****Fig. 3B**

3/10

**Fig. 4**





Fig. 5B

5/10




Fig. 6




Fig. 7

7/10




Fig. 8A




Fig. 8B

CODING REGION

8/10

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
GGAACAGTGT	CAAACATATA	TACAAGCTTG	ATGGTGAGAA	ATATTAGCAT	50
TAATACTGTC	ACTTGTGTGT	TAGCATATTA	TTTCTGATAT	ATAAATACTT	100
AGGAAATCT	ATTTTCTCA	TGCAAAAAGC	CACTTAACTT	CATCAATAAA	150
ATCGTTATCT	GCACCTAAGA	ATGATCTTCC	ATCATCTCTA	TGTTGACATA	200
CGTTTTATCA	TCCAGATTAT	CAATGAAAGT	CGAAAAGATT	ACAACTCCCT	250
CTGAAATATG	AATATTACAA	GTTTAGAGGG	CAAGTAAAGC	CAACACAAC	300
ACTTTGCAAG	GCGAGAACAA	GCAATATCAG	GGTGTACAT	TCTGTACATT	350
CGTTAGATAT	TTTACTTCTG	GGTCCAATCC	TTATTACACA	CTGCATTTCT	400
TCCAGGAAGT	TTGGATATAA	CTTTACAATG	CTTTATAACT	GATGAGTAGT	450
AAGCGTTGTA	TGCATTTTAG	AATCTATGCA	TTTCCCAATA	ATGCTGATAT	500
ATTCAATTAA	CTTAATTTAT	TACCAGCATC	ACATTCTTGC	ATTGATGCTC	550
GTCAGCTCGA	GAAGCGCTTC	CCATTCTCC	GCGCACCATA	CCACGTGGCG	600
TTGTCTTTC	TTGGGAACG	GGGTAGGGG	GTACTTACTT	CTAGGGGAAA	650
GACAGATCAG	TGCAGATCAC	CCCCGACTGT	GACACATTCT	TCCACATGTA	700
CACATGAAAG	GTTGTTATGC	AATATAATAC	ATTAGAAGGG	TATATTTATT	750
ACAATTACAA	TGGTTACGTT	TCTATTATTC	TCAAACACAA	TCTGATTGGT	800
CGCTACTTAA	TGGGGTATGT	ATAAAAGACG	CCTGGGTCAG	AACATCGATA	850
TTGCATCCGC	TTTCAGTCTT	CAGCTGACAC	ATGCTCTTTC	CCGTTTCTCA	900
CACAGCAACC	TACAACCATG	GATGATGATG	TTGCTGCAAT	GGTCTGTGAC	950
AACGGCTCCG	GCAATGTCAA	GGCCGGTTTT	GCCGGTGACG	ACGCTCCAG	1000
AGCTGTCTTC	CCCTCCATCG	TGGCCGTCC	TAGACATCAG	GTAACACCGT	1050
TTATTGTAC	CATGGTAACA	TAGAGGTCA	AGACCTGAAA	TATTTAGTTT	1100
CGCTACATT	TGCTCTCTGT	AGAATACACG	ACGTGCTACA	TAATGACAAA	1150
TGATTTCTTG	TTTCAGGGTG	TGATGGTTGG	TATGGGTCAG	AAAGACAGCT	1200
ACGTGGTGA	CGAGGCTCAG	TCCAAGAGAG	GTATCCTCAC	TCTCAAGTAT	1250
CCCATCGAGC	ACGGTATCGC	CACCAACTGG	GACGACATGG	AGAAGATCCG	1300
GCATCACACC	TTCTACAACG	AACCTCCAGT	GGCTCCAGAG	GAGCACCCTG	1350
TCCTYCTGAC	AGAGGCTCCC	CTCAACCCCA	AGGCCAACCG	TGAAAAGATG	1400
ACCCAGATCA	TGTTGAGAC	CTTCAACTCT	CCAGCTATGT	GTTGTTGCCAT	1450
CCAGGCTGTT	CTGTCTCTGT	ACGCTTCTGG	TGTTACCACG	GGTATTGTTT	1500
TGGACTCTGG	TGATGGTGT	ACCCACACTG	TTCCCATCTA		1540

Fig. 9

9/10







Fig. 10

10/10



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01477

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01K 61/00, 67/00; C12N 15/12, 15/18, 15/85, 15/87, 15/90

US CL : 119/234; 435/172.3, 320.1; 536/23.1, 23.5, 24.1; 800/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 119/234; 435/172.3, 320.1; 536/23.1, 23.5, 24.1; 800/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Proceedings of the National Academy of Sciences, USA, Volume 87, issued August 1990, V.D. Vacquier et al, "Species- specific sequences of abalone lysin, the sperm protein that creates a hole in the egg envelope", pages 5792-5796, see the entire document.	1-36
Y	Science, Volume 204, issued 27 April 1979, D.E. Morse et al, "Gamma-Aminobutyric acid, a Neurotransmitter, Induces Planktonic Abalone Larvae to Settle and Begin Metamorphosis", pages 407-410, see the entire document.	1-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T
* A* document defining the general state of the art which is not considered to be of particular relevance	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* E* earlier document published on or after the international filing date	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* O* document referring to an oral disclosure, use, exhibition or other means	* &* document member of the same patent family
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 APRIL 1995

Date of mailing of the international search report

21 APR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRUCE CAMPBELL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01477

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-36

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01477

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

BIOSIS, CHEM ABSTRACTS, DERWENT BIOTECHNOLOGY ABSTRACTS, AQUATIC SCIENCE AND FISHERIES ABSTRACTS

search terms: abalone, oyster, clam, squid, mollusk, scallop, snail, transgen?, transform?, transfect?, gene biotechnology, genetic engineering, gene expression, electroporation

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-36, drawn to transgenic mollusks and reagents and methods for making same.
Group II, claim(s) 37-38, drawn to methods of producing polyploid abalone.

The inventions listed as Groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
Groups I and II are distinct because the compositions and methods of I are not required for the methods of II and the methods of II are not required for the compositions and methods of I. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.